Vildagliptin/Metformin Krka 50 mg / 1000 mg tabletti, kalvopäällysteinen Phần Lan - Tiếng Phần Lan - Fimea (Suomen lääkevirasto)

vildagliptin/metformin krka 50 mg / 1000 mg tabletti, kalvopäällysteinen

krka, d.d., novo mesto - metformin hydrochloride, vildagliptin - tabletti, kalvopäällysteinen - 50 mg / 1000 mg - metformiini ja vildagliptiini

Vildagliptin/Metformin Krka 50 mg / 850 mg tabletti, kalvopäällysteinen Phần Lan - Tiếng Phần Lan - Fimea (Suomen lääkevirasto)

vildagliptin/metformin krka 50 mg / 850 mg tabletti, kalvopäällysteinen

krka, d.d., novo mesto - metformin hydrochloride, vildagliptin - tabletti, kalvopäällysteinen - 50 mg / 850 mg - metformiini ja vildagliptiini

Vildagliptin Mylan 50 mg tabletti Phần Lan - Tiếng Phần Lan - Fimea (Suomen lääkevirasto)

vildagliptin mylan 50 mg tabletti

mylan ab - vildagliptin - tabletti - 50 mg - vildagliptiini

Zomarist Liên Minh Châu Âu - Tiếng Phần Lan - EMA (European Medicines Agency)

zomarist

novartis europharm limited  - vildagliptiini, metformiinihydrokloridia - diabetes mellitus, tyyppi 2 - diabeetilla käytettävät lääkkeet - zomarist is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate.

Galvus Liên Minh Châu Âu - Tiếng Phần Lan - EMA (European Medicines Agency)

galvus

novartis europharm limited - vildagliptiini - diabetes mellitus, tyyppi 2 - diabeetilla käytettävät lääkkeet - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Jalra Liên Minh Châu Âu - Tiếng Phần Lan - EMA (European Medicines Agency)

jalra

novartis europharm limited - vildagliptiini - diabetes mellitus, tyyppi 2 - dipeptidyl peptidase 4 (dpp-4) inhibitors, drugs used in diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 ja 5. 1 käytettävissä olevista tiedoista eri yhdistelmistä).

Xiliarx Liên Minh Châu Âu - Tiếng Phần Lan - EMA (European Medicines Agency)

xiliarx

novartis europharm limited - vildagliptiini - diabetes mellitus, tyyppi 2 - diabeetilla käytettävät lääkkeet - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 ja 5. 1 käytettävissä olevista tiedoista eri yhdistelmistä).

Eucreas Liên Minh Châu Âu - Tiếng Phần Lan - EMA (European Medicines Agency)

eucreas

novartis europharm limited - vildagliptiini, metformiinihydrokloridia - diabetes mellitus, tyyppi 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

ACCUPRO 5 mg tabletti, kalvopäällysteinen Phần Lan - Tiếng Phần Lan - Fimea (Suomen lääkevirasto)

accupro 5 mg tabletti, kalvopäällysteinen

pfizer oy pfizer oy - quinaprili hydrochloridum - tabletti, kalvopäällysteinen - 5 mg - kinapriili

ACCUPRO 10 mg tabletti, kalvopäällysteinen Phần Lan - Tiếng Phần Lan - Fimea (Suomen lääkevirasto)

accupro 10 mg tabletti, kalvopäällysteinen

pfizer oy pfizer oy - quinaprili hydrochloridum - tabletti, kalvopäällysteinen - 10 mg - kinapriili